查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886301

生物相似藥市場－全球產業規模、佔有率、趨勢、機會和預測，依適應症、產品、地區和競爭格局分類，2020-2030年預測

Biosimilars Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Product, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球生物相似藥市場規模將從2024年的310.7億美元成長到2030年的423.6億美元，年複合成長率為5.30%。生物相似藥是與已核准的原廠生物藥（即參考產品）高度相似的生物藥品，在安全性、純度和有效性方面均無臨床意義上的差異。全球生物相似藥市場成長的主要促進因素是許多重磅生物藥專利即將到期，促使人們尋求更經濟實惠的替代療法，以及全球慢性病盛行率的不斷上升。

市場概覽
預測期 2026-2030
市場規模：2024年 310.7億美元
市場規模：2030年 423.6億美元
複合年成長率：2025-2030年 5.30%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

主要市場促進因素

全球生物相似藥市場擴張的根本驅動力在於許多高價值生物製劑的專利即將到期，這為更經濟實惠的替代藥物創造了巨大機會。製藥業目前正面臨2025年至2030年間高達2,360億美元的專利懸崖，屆時將有近70種重磅藥物失去專利保護，並向生物相似藥敞開大門，展開競爭。

主要市場挑戰

生物相似藥固有的生產複雜性和高昂成本嚴重阻礙了全球生物相似藥市場的擴張。由於生物相似藥複雜的生物學特性，其研發和生產需要大量的研發投入、高度專業化的生產設施以及嚴格的純化製程。

主要市場趨勢

全球生物相似藥市場受到GLP-1受體激動劑生物相似藥市場擴張的顯著影響，這標誌著市場策略重點正轉向高需求治療領域。這一趨勢旨在滿足大量患有第2型糖尿病和肥胖症等慢性疾病的患者的需求，可望擴大藥物可近性並降低醫療成本。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球生物相似藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症分類（腫瘤、發炎和自體免疫疾病、慢性疾病、血液疾病、生長激素缺乏症、傳染病、其他）
    • 副產物（單株抗體、胰島素、粒細胞集落刺激因子、紅血球生成素、重組人類生長激素、依那西普、促卵泡素、特立帕肽、干擾素、抗凝血劑、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美生物相似藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲生物相似藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太生物相似藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲生物相似藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲生物相似藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球生物相似藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Dr. Reddy's Laboratories Ltd.
  • Sandoz Group AG
  • Coherus Biosciences
  • Viatris Inc.
  • Bio-Thera Solutions
  • Pfizer Inc.
  • Apobiologix
  • Teva Pharmaceuticals
  • Biocon Ltd
  • Reliance Life Sciences

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22689

The Global Biosimilars Market will grow from USD 31.07 Billion in 2024 to USD 42.36 Billion by 2030 at a 5.30% CAGR. Biosimilars are biological medical products highly similar to an already approved original biologic, known as the reference product, demonstrating no clinically meaningful differences in safety, purity, and effectiveness. The global biosimilars market's growth is primarily driven by the imminent patent expiry of numerous blockbuster biologics, compelling the demand for more affordable therapeutic alternatives, alongside the increasing prevalence of chronic diseases globally.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 31.07 Billion
Market Size 2030USD 42.36 Billion
CAGR 2025-20305.30%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

The global biosimilars market expansion is fundamentally propelled by the imminent patent expiration of numerous high-value biologic drugs, creating substantial opportunities for more affordable alternatives. The pharmaceutical industry is currently navigating a significant $236 billion patent cliff projected between 2025 and 2030, with nearly 70 blockbuster products set to lose exclusivity and open their therapeutic areas to biosimilar competition. This widespread loss of exclusivity acts as a primary catalyst, enabling biosimilar manufacturers to develop and launch products that directly compete with established biologics.

Key Market Challenges

The inherent manufacturing complexities and high associated costs represent a significant impediment to the global biosimilars market's expansion. Developing and producing biosimilar products requires extensive investment in research, highly specialized manufacturing facilities, and stringent purification processes due to their intricate biological nature. These factors directly contribute to extended development timelines and elevated capital expenditure for biosimilar manufacturers, creating substantial financial outlay and technical hurdles.

Key Market Trends

The global biosimilars market is significantly influenced by the expansion into GLP-1 agonist biosimilars, marking a strategic pivot towards high-demand therapeutic areas. This trend addresses the substantial patient populations grappling with chronic conditions such as type 2 diabetes and obesity, promising to broaden access and alleviate healthcare costs. The entry of biosimilar versions of these highly effective drugs is poised to intensify competition and foster innovation within this lucrative segment.

Key Market Players

  • Dr. Reddy's Laboratories Ltd.
  • Sandoz Group AG
  • Coherus Biosciences
  • Viatris Inc.
  • Bio-Thera Solutions
  • Pfizer Inc.
  • Apobiologix
  • Teva Pharmaceuticals
  • Biocon Ltd
  • Reliance Life Sciences

Report Scope:

In this report, the Global Biosimilars Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biosimilars Market, By Indication:

  • Oncology
  • Inflammatory and autoimmune diseases
  • Chronic diseases
  • Blood disorders
  • Growth hormone deficiency
  • Infectious diseases
  • Others

Biosimilars Market, By Product:

  • Monoclonal antibodies
  • Insulin
  • Granulocyte colony-stimulating factor
  • Erythropoietin
  • Recombinant human growth hormone
  • Etanercept
  • follitropin
  • Teriparatide
  • Interferons
  • Anticoagulants
  • Others

Biosimilars Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biosimilars Market.

Available Customizations:

Global Biosimilars Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biosimilars Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Oncology, Inflammatory and autoimmune diseases, Chronic diseases, Blood disorders, Growth hormone deficiency, Infectious diseases, Others)
    • 5.2.2. By Product (Monoclonal antibodies, Insulin, Granulocyte colony-stimulating factor, Erythropoietin, Recombinant human growth hormone, Etanercept, follitropin, Teriparatide, Interferons, Anticoagulants, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Biosimilars Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Product
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biosimilars Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Product
    • 6.3.2. Canada Biosimilars Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Product
    • 6.3.3. Mexico Biosimilars Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Product

7. Europe Biosimilars Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Product
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Biosimilars Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Product
    • 7.3.2. France Biosimilars Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Product
    • 7.3.3. United Kingdom Biosimilars Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Product
    • 7.3.4. Italy Biosimilars Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Product
    • 7.3.5. Spain Biosimilars Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Product

8. Asia Pacific Biosimilars Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Product
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Biosimilars Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Product
    • 8.3.2. India Biosimilars Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Product
    • 8.3.3. Japan Biosimilars Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Product
    • 8.3.4. South Korea Biosimilars Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Product
    • 8.3.5. Australia Biosimilars Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Product

9. Middle East & Africa Biosimilars Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Product
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Biosimilars Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Product
    • 9.3.2. UAE Biosimilars Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Product
    • 9.3.3. South Africa Biosimilars Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Product

10. South America Biosimilars Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Product
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Biosimilars Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Product
    • 10.3.2. Colombia Biosimilars Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Product
    • 10.3.3. Argentina Biosimilars Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Product

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Biosimilars Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Dr. Reddy's Laboratories Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sandoz Group AG
  • 15.3. Coherus Biosciences
  • 15.4. Viatris Inc.
  • 15.5. Bio-Thera Solutions
  • 15.6. Pfizer Inc.
  • 15.7. Apobiologix
  • 15.8. Teva Pharmaceuticals
  • 15.9. Biocon Ltd
  • 15.10. Reliance Life Sciences

16. Strategic Recommendations

17. About Us & Disclaimer